Corpus ID: 73845569

Revisión sistemática de la literatura: tratamiento del dolor central en esclerosis multiple

  title={Revisión sistemática de la literatura: tratamiento del dolor central en esclerosis multiple},
  author={Art{\'i}culo Original and D. Castillo and C. M. Benavides},
INTRODUCCION: el dolor es un sintoma muy comun en pacientes con Esclerosis Multiple (EM), 42 al 65 por ciento de los enfermos lo presentan, y es calificado como el sintoma mas severo entre el 8 y el 32 por ciento. Todos los sindromes dolorosos centrales se presentan por lesion o disfuncion del sistema nervioso central, causando discapacidad severa y deterioro de la calidad de vida de los pacientes. 


Pain in multiple sclerosis.
It is found that the incidence of clinically significant pain in patients with multiple sclerosis, excluding headache and paresthesia, was 28.8%. Expand
Central pain in multiple sclerosis — prevalence and clinical characteristics
In the present study, questionnaires were sent to all 429 patients with definite MS and central pain (CP) in MS and its characteristics were defined. Expand
Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems.
It is hypothesized that the action of this combined therapy may relate to activation of the noradrenergic locus coeruleus/lateral tegmentum (LC/LT) system which has the potential to influence the functioning of large areas of the brain and spinal cord. Expand
Pain syndromes in multiple sclerosis
MS patients with pain were similar to the pain-free group in mean age of onset, average duration of disease, spinal cord involvement, and mean rating on Kurtzke Disability Status Scale, but differed in sex ratio with a higher female-to-male ratio in the pain group. Expand
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful. Expand
Epidemiology of multiple sclerosis: a critical overview.
  • A. Sadovnick, G. Ebers
  • Medicine
  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 1993
It is concluded that the epidemiology of MS cannot be explained by any single known environmental or genetic factor(s) in isolation and a combination of a heterogeneous distribution of both genetic and environmental factors appears to be required. Expand
Morphine responsiveness in a group of well‐defined multiple sclerosis patients: A study with i.v. morphine
Only a minority of the patients with CP due to MS responded to morphine and only at high doses, in accord with experimental studies indicating that neuropathic pain is poorly responsive but not totally unresponsive to opioids. Expand
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage. Expand
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo. Expand
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated. Expand